Health Care Supplies

Gongdong Medical

Gongdong Medical released FY2025 Q4 earnings on April 23 After-Market (BJT), actual revenue CNY 290.62 M, actual EPS CNY -0.0846

Gongdong Medical released FY2025 annual earnings on April 23 After-Market (BJT), actual revenue CNY 1.136 B (forecast CNY 1.256 B), actual EPS CNY 0.23 (forecast CNY 0.6092)

Gongdong Medical released FY2026 Q1 earnings on April 23 After-Market (BJT), actual revenue CNY 288.59 M, actual EPS CNY 0.15

Gongdong Medical to Release FY2026 Q1 Earnings on April 24 After-Market BJT

Gongdong Medical to Release FY2025 Annual Earnings on April 24 After-Market (BJT), Forecast Revenue CNY 1.256 B, EPS CNY 0.6092

Gongdong Medical released FY2025 Q3 earnings on October 29 During-Market (BJT), actual revenue CNY 288.16 M, actual EPS CNY 0.0998

Gongdong Medical released FY2025 9 Months Earnings on October 29 During-Market (BJT), actual revenue CNY 845.08 M, actual EPS CNY 0.328

Gongdong Medical to Release FY2025 Q3 Earnings on October 30 During-Market (BJT)

Gongdong Medical released FY2025 Q2 earnings on August 25 After-Market (BJT), actual revenue CNY 292.45 M, actual EPS CNY 0.1081

Gongdong Medical released FY2025 Semi-Annual earnings on August 25 After-Market (BJT), actual revenue CNY 556.92M, actual EPS CNY 0.23

Gongdong Medical to Release FY2025 Semi-Annual Earnings on August 26, 2025 (BJT)

Gongdong Medical's Shareholders and General Manager Complete Selling Plan

AOD Medical Director Sells Shares

Gongdong Medical Reports Revenue Decline in Q1 2025

Gongdong Medical released FY2025 Q1 earnings on April 25 After-Market (BJT), actual revenue CNY 264.48 M, actual EPS CNY 0.12

Arch Dong Medical Reports 57.28% Net Profit Growth in 2024

Gongdong Medical released FY2024 Annual Earnings on April 21 After-Market (BJT), actual revenue CNY 1.115 B (forecast CNY 1.303 B), actual EPS CNY 0.78 (forecast CNY 1.0234)

Gongdong Medical released FY2024 Q4 earnings on April 21 After-Market (BJT), actual revenue CNY 279.18 M, actual EPS CNY 0.139

Gongdong Medical to Release FY2025 Q1 Earnings on April 26 After-Market BJT

Gongdong Medical to Release FY2024 Earnings on April 22 After-Market BJT, Forecast Revenue CNY 1.303 B, EPS CNY 1.4328

605369

300496

Zhiran Medical recently completed a 300 million yuan A+ round of financing, led by Thundersoft. The funds will be used to advance large-scale clinical trials and the iteration of high-throughput flexible electrode products. The company has broken through core technologies such as stretchable flexible electrodes and domestically produced neural chips, and has completed the first domestic clinical implantation with over 100 channels. It plans to initiate large-scale registration clinical trials in 2026 to promote the application transformation of invasive brain-machine interfaces

Wallstreetcn

Thundersoft

Zhiran Medical has secured another 300 million yuan in A+ round financing within six months, accelerating the clinical implementation of invasive brain-machine interfaces

Gongdong Medical announced that its shareholder Taizhou Jinch Investment Management Partnership will reduce its holdings by 540,240 shares through centralized bidding from October 9 to 30, 2025, decreasing its shareholding ratio from 64.21% to 63.96%. This change in equity touches the 1% threshold and is part of the implementation of the reduction plan, which does not affect the company's controlling rights, and the reduction plan has not yet been fully implemented

Zhitong

Gongdong Medical: Shareholding reduction by shareholders holding over 5% leads to a change in equity reaching 1%

According to the announcement from Dolphin Research, Gongdong Medical stated that within three months after the 15 trading days from the date of the announcement, the company's controlling shareholder and actual controller, Shi Huiyong, intends to reduce his holdings by no more than 4.4099 million shares through block trading, and the total number of shares reduced within any consecutive 90 days shall not exceed 2% of the company's total share capital. Jincheng Investment intends to reduce its holdings by no more than 2.2049 million shares through centralized bidding trading, which shall not exceed 1% of the company's total share capital

Gongdong Medical's controlling shareholders plan to reduce their holdings by no more than 3%

Gongdong Medical's 2025 semi-annual report shows that in the first half of the year, operating income was 557 million yuan, a year-on-year increase of 0.58%; net profit attributable to the parent company was 50.3493 million yuan, a year-on-year decrease of 47.16%. The decline in net profit was mainly affected by U.S. tariff policies and domestic medical procurement policies, leading to a decrease in the selling prices of some products and a reduction in gross profit. In addition, losses from the investment income of the acquisition of Jindongsheng, fluctuations in the U.S. dollar exchange rate, and a decrease in interest income also impacted net profit

Gongdong Medical: Net profit for the first half of the year was 50.3493 million yuan, a year-on-year decrease of 47.16%

According to the Zhitong Finance APP, Gongdong Medical announced that the share reduction plan of its shareholder Jinchi Investment and General Manager Zhong Weifeng has been completed. Jinchi Investment has cumulatively reduced its holdings by 1.5757 million shares through centralized bidding, and Mr. Zhong Weifeng has cumulatively reduced his holdings by 294,900 shares through centralized bidding

Gongdong Medical shareholder Jinchit Investment has cumulatively reduced its holdings by 1.5757 million shares

Gongdong Medical released its Q1 2025 performance report, with operating revenue of 264 million yuan, a year-on-year decrease of 2.74%; net profit attributable to the parent company of 27.4125 million yuan, a year-on-year decrease of 39.23%; net profit after deducting non-recurring gains and losses of 34.744 million yuan, a year-on-year decrease of 20.03%; basic earnings per share of 0.17 yuan/share

Gongdong Medical released its first-quarter performance, with a net profit attributable to the parent company of 27.4125 million yuan, a year-on-year decrease of 39.23%

Gongdong Medical released its 2024 annual report, with revenue of 1.115 billion yuan, a year-on-year increase of 14.37%; net profit attributable to the parent company of 172 million yuan, a year-on-year increase of 57.28%; net profit excluding non-recurring items of 168 million yuan, a year-on-year increase of 56.18%; basic earnings per share of 1.09 yuan. The company plans to distribute a cash dividend of 4.00 yuan for every 10 shares and to increase its capital by transferring 4 shares for every 10 shares from the statutory surplus reserve

Gongdong Medical released its 2024 annual performance, with a net profit attributable to the parent company of 172 million yuan, a year-on-year increase of 57.28%

Gongdong Medical announced that the 13th meeting of the third board of directors reviewed and approved the "Proposal on the Appointment of the Company's Deputy General Manager," agreeing to appoint Mr. Zhu Yong as the Deputy General Manager of the company, with a term starting from the date of approval by the board of directors until the expiration of the term of the third board of directors. Mr. Zhu Yong, born in November 1979, previously served as the financial manager, deputy director, and financial director of Zhejiang Haixiang Pharmaceutical Co., Ltd., and is currently the financial director of the company

Gongdong Medical: Appointed Mr. Zhu Yong as the company's Deputy General Manager

Gongdong Medical announced that Jinch Investment plans to reduce its holdings by no more than 1,575,784 shares, accounting for approximately 1% of the company's total share capital, through centralized bidding trading within 3 months after 15 trading days. At the same time, the company's director and general manager Zhong Weifeng also plans to reduce his holdings by no more than 302,158 shares, accounting for approximately 0.19% of the total share capital

Gongdong Medical: Some shareholders plan to reduce their holdings by a total of no more than 1.19% of the shares

Gongdong Medical announced that shareholder Jinchit Investment plans to reduce its holdings by no more than 1.5758 million shares, accounting for 1% of the company's total share capital. The company's director and general manager Zhong Weifeng plans to reduce his holdings by no more than 302,200 shares, accounting for 0.19% of the company's total share capital. The reduction period is from March 11, 2025, to June 10, 2025, and the reduction price will not be lower than the issue price of the initial public offering

Gongdong Medical(605369.SH)